Recent Comments

Comment RSS

Glioblastoma News and Research RSS Feed - Glioblastoma News and Research

Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.

Cancer promoting gene identified

21. November 2009 03:08
Virginia Commonwealth University Massey Cancer Center and VCU Institute of Molecular Medicine researchers have identified a gene that may play a pivotal role in two processes that are essential for tumor development, growth and progression to metastasis. Scientists hope the finding could lead to an effective therapy to target and inhibit the expression of this gene resulting in inhibition of cancer growth. [More]

World's first intra-arterial cerebral infusion of Avastin directly into a patient's malignant brain tumor

18. November 2009 04:43
Neurosurgeons from NewYork-Presbyterian Hospital/Weill Cornell Medical Center performed the world's first intra-arterial cerebral infusion of Avastin (bevacizumab) directly into a patient's malignant brain tumor. This novel intra-arterial (IA) technique may expose the cancer to higher doses of the drug therapy, while possibly sparing the patient common side effects of receiving the drug intravenously (IV) or throughout their body. [More]

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

16. November 2009 10:40
Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology. [More]

Erbitux recognized as one of the major clinical cancer advances of 2009

16. November 2009 09:21
The American Society of Clinical Oncology (ASCO) has once again recognized Erbitux® (cetuximab) as one of the major clinical cancer advances of 2009. This year Erbitux was selected by ASCO for providing the first significant increase in survival for 30 years in the treatment of patients with 1st-line recurrent and/or metastatic squamous cell carcinoma of the head and neck (SCCHN). [More]

UT Southwestern Medical Center awarded $42M for basic and patient-oriented research

13. November 2009 00:08
UT Southwestern Medical Center has been awarded more than $42 million to date for basic and patient-oriented research from the American Recovery and Reinvestment Act of 2009, the $787 billion stimulus package President Barack Obama signed into law in February. [More]

Bradmer Pharmaceuticals reports financial results for the third quarter of 2009

12. November 2009 07:37
Bradmer Pharmaceuticals Inc. today announced its 2009 third quarter financial results. [More]

Posted in: Business / Finance

Tags: , , , , ,

Peregrine Pharmaceuticals' bavituximab PS-targeting antibody demonstrates potent anti-tumor activity

11. November 2009 01:51
Peregrine Pharmaceuticals, Inc. today announced that a newly published study shows that a phosphatidylserine (PS)-targeting antibody similar to the company's lead product candidate bavituximab demonstrated potent anti-tumor activity when combined with radiation in a model of aggressive brain cancer, doubling the survival time of test animals and producing long-term cures. [More]

Celldex announces third quarter and nine-month period results; acquires a net loss of $7.2 million

4. November 2009 07:47
Celldex Therapeutics, Inc. today reported financial results for the third quarter and nine-month period ended September 30, 2009. Celldex reported a net loss of $7.2 million, or $0.45 per share, for the third quarter of 2009 compared to a net loss of $7.7 million, or $0.49 per share, for the third quarter of 2008. [More]

MagForce Nanotechnologies completes clinical trial of Nano-Cancer therapy in glioblastoma patients

4. November 2009 03:12
MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. [More]

Posted in: Device / Technology News | Medical Condition News | Pharmaceutical News

Tags: , , ,

MagForce Nanotechnologies announces successful completion of its Nano-Cancer therapy trials

4. November 2009 00:07
MagForce Nanotechnologies AG, the Berlin-based medical technology company majority owned by Nanostart AG, today announced the successful completion of final trials demonstrating the efficacy of its Nano-Cancer® therapy in patients with recurrent glioblastoma, a frequent form of brain tumor which is highly malignant. The actual study results significantly exceeded the study objective. [More]

Posted in: Medical Science News | Medical Condition News

Tags: , , , , , ,

UCSF scientists receive grants to advance stem cell based strategies for diabetes and brain tumors

30. October 2009 05:29
Two teams of UCSF scientists have received grants from the California Institute for Regenerative Medicine to advance their stem cell based strategies for treating diabetes and brain tumors. [More]

Third-quarter 2009 financial results of Antigenics announced

29. October 2009 07:45
Antigenics Inc. reported today its results for the quarter ended September 30, 2009. The company incurred a net loss attributable to common stockholders of $10.8 million, or $0.13 per share, basic and diluted, for the third quarter of 2009, compared with a net loss attributable to common stockholders in the third quarter of 2008 of $11.4 million, or $0.17 per share, basic and diluted. [More]

Moores UCSD Cancer Center awarded $20 million for cancer research

28. October 2009 16:30
Researchers led by Moores UCSD Cancer Center Director Dennis A. Carson, MD, professor of medicine, and Catriona Jamieson, MD, PhD, assistant professor of medicine and director of the Cancer Stem Cell Research Program at the Moores UCSD Cancer Center have been awarded $20 million over four years to develop novel drugs against leukemia stem cells. [More]

ImmunoCellular Therapeutics presents additional data from its ICT-107 Phase I clinical trial

27. October 2009 09:16
ImmunoCellular Therapeutics, Ltd., a biotechnology company that is focused on the development of novel immune-based cancer therapies, today announced additional data from its Phase I clinical trial evaluating ICT-107, the Company’s dendritic-cell based cancer vaccine product candidate for the treatment of glioblastoma multiforme (GBM). [More]

Report on immunotherapies and vaccines for nontraditional indications

27. October 2009 07:23
Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications [More]
News-Medical.Net provides this medical information service in accordance with these terms and conditions. Please note that medical information found on this website is designed to support, not to replace the relationship between patient and physician/doctor and the medical advice they may provide.